DE69408135T2 - Ospc-antigen-impfstoffe immunogene zusammensetzung zur vorbeugung und behandlung von lyme-krankheit und rekombinante verfahren zur herstellung von derartige antigene - Google Patents

Ospc-antigen-impfstoffe immunogene zusammensetzung zur vorbeugung und behandlung von lyme-krankheit und rekombinante verfahren zur herstellung von derartige antigene

Info

Publication number
DE69408135T2
DE69408135T2 DE69408135T DE69408135T DE69408135T2 DE 69408135 T2 DE69408135 T2 DE 69408135T2 DE 69408135 T DE69408135 T DE 69408135T DE 69408135 T DE69408135 T DE 69408135T DE 69408135 T2 DE69408135 T2 DE 69408135T2
Authority
DE
Germany
Prior art keywords
antigens
ospc
vaccinals
antigue
preventing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69408135T
Other languages
English (en)
Other versions
DE69408135D1 (de
Inventor
Ian Livey
Brian Crowe
Friedrich Dorner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oesterreichisches Institut fuer Haemoderivate
Original Assignee
Immuno AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuno AG filed Critical Immuno AG
Application granted granted Critical
Publication of DE69408135D1 publication Critical patent/DE69408135D1/de
Publication of DE69408135T2 publication Critical patent/DE69408135T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69408135T 1993-04-29 1994-04-29 Ospc-antigen-impfstoffe immunogene zusammensetzung zur vorbeugung und behandlung von lyme-krankheit und rekombinante verfahren zur herstellung von derartige antigene Expired - Fee Related DE69408135T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5386393A 1993-04-29 1993-04-29
PCT/EP1994/001365 WO1994025596A2 (en) 1993-04-29 1994-04-29 IMMUNOGENIC FORMULATION OF OspC ANTIGEN VACCINES FOR THE PREVENTION AND TREATMENT OF LYME DISEASE AND RECOMBINANT METHODS FOR THE PREPARATION OF SUCH ANTIGENS

Publications (2)

Publication Number Publication Date
DE69408135D1 DE69408135D1 (de) 1998-02-26
DE69408135T2 true DE69408135T2 (de) 1998-06-10

Family

ID=21987063

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69408135T Expired - Fee Related DE69408135T2 (de) 1993-04-29 1994-04-29 Ospc-antigen-impfstoffe immunogene zusammensetzung zur vorbeugung und behandlung von lyme-krankheit und rekombinante verfahren zur herstellung von derartige antigene

Country Status (16)

Country Link
EP (1) EP0701612B1 (de)
JP (1) JPH08509371A (de)
AT (1) ATE162550T1 (de)
AU (1) AU683260B2 (de)
CA (1) CA2161534A1 (de)
CZ (1) CZ289212B6 (de)
DE (1) DE69408135T2 (de)
DK (1) DK0701612T3 (de)
ES (1) ES2114687T3 (de)
FI (1) FI955150A (de)
HR (1) HRP940279B1 (de)
HU (1) HU217024B (de)
NO (1) NO954318L (de)
PL (1) PL178775B1 (de)
SK (1) SK279968B6 (de)
WO (1) WO1994025596A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5915049A (en) * 1992-02-25 1999-06-22 Pfu Limited Binarization system for an image scanner
US7008625B2 (en) 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
DE69718903T2 (de) * 1996-05-02 2003-12-04 Dakocytomation Denmark As Glos Verwendung von aus osp-c abgeleiteten peptidefragmenten für diagnostische methoden
US6716574B2 (en) 1996-05-02 2004-04-06 Dako A/S Osp-C derived peptide fragments
US5846946A (en) * 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
AT405940B (de) * 1996-06-21 1999-12-27 Immuno Ag Verfahren zur gewinnung und reinigung von rekombinantem, nicht-lipidiertem osp-protein
DE19629543C2 (de) * 1996-07-22 1999-02-11 Immuno Ag Immunassay zum Nachweis von anti-B. burgdorferi Antikörpern und Verfahren zur Serodiagnose bei Lyme Borreliose, diagnostische Mittel und Testkits zur Durchführung der Verfahren
DE19740735A1 (de) 1997-09-16 1999-03-18 Max Planck Gesellschaft Arzneimittel zur Therapie einer manifesten Lyme-Borreliose
ATE386805T1 (de) 1998-07-31 2008-03-15 Gundersen Lutheran Medical Fou Verwendungen eines borreliaziden epitops des aussermembranproteins c von borrelia burgdorferi (ospc) als impstoff
WO2000078966A1 (en) * 1999-06-18 2000-12-28 Research Foundation Of State University Of New York Groups of borrelia burgdorferi and borrelia afzelii that cause lyme disease in humans
AU2001285049A1 (en) 2000-08-18 2002-03-04 Brookhaven Sciences Associates, Llc Altered ospa of borrelia burgdorferi
GB2414667A (en) 2004-06-03 2005-12-07 Isis Innovation Vaccine compositions of N. meningitidis PorA and FetA antigens
EP1957520A4 (de) * 2005-11-29 2009-05-27 Univ Virginia Commonwealth Polyvalentes chimärisches ospc-vaccinogen und diagnostisches antigen
EP2077856B1 (de) * 2006-11-03 2015-08-12 Intervet International BV Lyme-impfstoff für hunde
CZ301244B6 (cs) * 2007-11-14 2009-12-16 Bioveta, A.S. Univerzální vakcína k lécbe a prevenci Lymeské borreliózy pro humánní a veterinární použití a zpusob její výroby
CZ301548B6 (cs) * 2008-08-20 2010-04-14 Bittner@Libor Univerzální preparát ke zvýšení obranyschopnosti, prevenci, profylaxi a lécbe Lymeské boreliózy pro humánní a veterinární použití, zpusob jeho výroby a použití

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221363B1 (en) * 1991-07-11 2001-04-24 Baxter Aktiengesellschaft Vaccine for the prevention of lyme disease

Also Published As

Publication number Publication date
AU6722994A (en) 1994-11-21
JPH08509371A (ja) 1996-10-08
FI955150A0 (fi) 1995-10-27
WO1994025596A2 (en) 1994-11-10
NO954318L (no) 1995-12-29
PL178775B1 (pl) 2000-06-30
HRP940279A2 (en) 1997-10-31
SK279968B6 (sk) 1999-06-11
CZ289212B6 (cs) 2001-12-12
CA2161534A1 (en) 1994-11-10
EP0701612B1 (de) 1998-01-21
PL311301A1 (en) 1996-02-05
ES2114687T3 (es) 1998-06-01
DK0701612T3 (da) 1998-09-21
NO954318D0 (no) 1995-10-27
AU683260B2 (en) 1997-11-06
HUT72923A (en) 1996-06-28
HU9502002D0 (en) 1995-08-28
EP0701612A1 (de) 1996-03-20
WO1994025596A3 (en) 1994-12-22
SK134195A3 (en) 1996-05-08
FI955150A (fi) 1995-12-28
ATE162550T1 (de) 1998-02-15
DE69408135D1 (de) 1998-02-26
CZ283995A3 (en) 1996-03-13
HRP940279B1 (en) 2000-12-31
HU217024B (hu) 1999-11-29

Similar Documents

Publication Publication Date Title
DE69408135D1 (de) Ospc-antigen-impfstoffe immunogene zusammensetzung zur vorbeugung und behandlung von lyme-krankheit und rekombinante verfahren zur herstellung von derartige antigene
ATE181572T1 (de) Ospa proteine von borrelia burgdorferi untergruppen, dafür kodierende gene sowie impfstoffe
YU49370B (sh) Postupak za pripremanje vakcine protiv lajmske bolesti
DE69637642D1 (de) Und kombinierte zusammensetzungen und deren verwendung
ATE448301T1 (de) Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten
DK0503648T3 (da) CD2-bindingsdomæne af lymfocytfunktion-associeret antigen 3
ATE61228T1 (de) Immunogener protein- oder peptidkomplex, verfahren zur herstellung dieses komplexes und seine verwendung als immunstimulans und als impfstoff.
DE69618601D1 (de) Herstellung von einer immunantwort gegen prostat-spezifisches antigen (psa)
DE69720056D1 (de) Chlamydia-impfstoffe und immunogene chlamydia-zusammensetzungen, die ein antigen der äusseren membran enthalten, sowie verfahren zu deren herstellung
PT726955E (pt) Proteinas quimericas compreendendo polipeptidos borrelia: suas utilizacoes
DK0555276T3 (da) Immunogene komplekser, især iscomer
DE69101634D1 (de) Rekombinant hergestellte blutfaktoren, verfahren zur exprimierung besagter blutfaktoren sowie in besagtem prozess verwendeter rekombinanter vaccina-virus.
DE69122240D1 (de) Antigen-wirkende proteine von borrelia burgdorferi
DK0425082T3 (da) Vacciner
ATE85058T1 (de) Jodhaltige polymere mit skeletten von dextran, verfahren zu ihrer herstellung und ihre verwendungen als kontrastmittel.
GB2176191A (en) Antigens of plasmodium falciparum
ATE310803T1 (de) Verfahren zur produktion von verstärkt antigen wirkenden heliobacter sp. und vakzine die diesen enthalten
FI973335A (fi) Helicobacter pylori-antigeeni
DE69119230D1 (de) Schützende antikörper erregende plasmodium falciparum antigene und deren verwendung in impfstoffen
WO2000018429A3 (en) Vaccine based on attenuated $i(haemophilus somnus)
DE59207362D1 (de) Monoklonale Antikörper gegen den Plasmin-Antiplasmin Komplex, Verfahren zu ihrer Herstellung sowie ihre Verwendung
DK43991A (da) Allele varianter af plasmodium falciparum merozoitoverfladeantigen
MY106940A (en) Allelic variants of plasmodium falciparum merozoite surface antigen.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee